(4-溴苯基)环丙基甲酮 | 6952-89-2

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (4-溴苯基)环丙基甲酮
• 英文名称: (4-bromophenyl)(cyclopropyl)methanone
• 英文别名: 4-bromophenyl cyclopropyl ketone；<4-Brom-phenyl>-cyclopropyl-keton；(4-bromophenyl)-cyclopropylmethanone
• CAS: 6952-89-2
• 化学式: C₁₀H₉BrO
• mdl: MFCD00019227
• 分子量: 225.085
• InChiKey: QTHHOINSCNBYQO-UHFFFAOYSA-N

物化性质

• 熔点：
  40.0 to 44.0 °C
• 沸点：
  204°C/10mmHg(lit.)
• 密度：
  1.45
• 保留指数：
  1653
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与不相容的材料接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2914700090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  密封储存，应存放在阴凉干燥的库房中。

SDS

Name:	(4-Bromophenyl)cyclopropylmethanone Material Safety Data Sheet
Synonym:
CAS:	6952-89-2

Section 1 - Chemical Product MSDS Name:(4-Bromophenyl)cyclopropylmethanone Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6952-89-2	(4-Bromophenyl)cyclopropylmethanone	99	230-130-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6952-89-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.4500g/cm3
Molecular Formula: C10H9BrO
Molecular Weight: 225.09

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6952-89-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(4-Bromophenyl)cyclopropylmethanone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 6952-89-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6952-89-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6952-89-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (4-溴苯基)环丙基甲酮 在 CuCN 盐酸 、 sodium hydroxide 、 三氯化铁 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 以14.57 g (85%)的产率得到4-(环丙基羰基)苯甲腈
  参考文献：
  名称：

  Substituted 5-membered ring heterocycles, their preparation and their use

  摘要：

  本发明涉及一般式（I）的5-环杂环化合物，其中W、Y、Z、B、D、E和R以及b、c、d、e、f、g和h如描述中所示；以及其制备方法，以及它们作为抑制血小板聚集、癌细胞转移和破骨细胞附着于骨表面的用途。

  公开号：

  US05981492A1
• 作为产物：
  描述：

  以 二氯甲烷 为溶剂， 反应 6.0h， 以39.7 mg的产率得到(4-溴苯基)环丙基甲酮
  参考文献：
  名称：

  通过高价碘氧化环丁醇向环丙基酮的轻度环收缩

  摘要：

  已经开发出碘介导的环丁醇的氧化环收缩。该反应可以在温和且环保的条件下合成各种芳基环丙基酮。反应中可以很好地耐受各种官能团，包括芳族或烷基卤化物，醚，酯，酮，烯烃，甚至醛。这与传统的合成方法相反，在传统的合成方法中，官能团的耐受性通常很差。碘氧化系统的可调性也突出了该方法的实用性。具体而言，将碘（III）试剂与适当的碱结合使用可使反应适应一系列富挑战性的富电子芳烃底物。在此也显示了该反应的简便可扩展性。

  DOI：

  10.1002/adsc.201701237

文献信息

• [EN] SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY<br/>[FR] COMPOSÉS SULFONAMIDES AYANT UNE ACTIVITÉ D'ANTAGONISTE DE TRPM8
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2012124825A1

  公开（公告）日：2012-09-20

  Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.

  提供具有TRPM8拮抗活性的磺胺类化合物。公式（I）的磺胺类化合物或其药学上可接受的盐，或其前药：（I）其中环A是由（a）吡啶与苯环融合；或（b）吡啶与单环芳香杂环融合而成的双环芳香杂环，环A与构成环A的吡啶环上的氮原子相邻的碳原子上的磺酰氨基团结合，环B是（a）单环或双环芳香烃；（b）单环或双环脂环烃；（c）单环或双环芳香杂环；或（d）单环或双环非芳香杂环，环C是（a）苯环；或（b）单环芳香杂环，其他符号与规范中定义的相同。
• Lewis Base-Promoted Ring-Opening 1,3-Dioxygenation of Unactivated Cyclopropanes Using a Hypervalent Iodine Reagent
  作者：Matthew H. Gieuw、Zhihai Ke、Ying-Yeung Yeung

  DOI：10.1002/anie.201713422

  日期：2018.3.26

  A facile and effective system has been developed for the regio‐ and chemoselective ring‐opening/electrophilic functionalization of cyclopropanes through C−C bond activation by [bis(trifluoroacetoxy)iodo]benzene with the aid of the Lewis basic promoter p‐toluenesulfonamide. The p‐toluenesulfonamide‐promoted system works well for a wide range of cyclopropanes, resulting in the formation of 1,3‐diol products

  已经开发了一种简便有效的系统，借助路易斯（Lewis）碱性促进剂对甲苯磺酰胺，通过[双（三氟乙酰氧基）碘]苯的CC键活化，对环丙烷的区域和化学选择性开环/亲电子官能化。所述p -toluenesulfonamide促进的系统可以很好地用于宽范围的环丙烷，得到1,3-二醇产物以良好产率选择性和区域选择性的形成。
• 一种芳基或杂芳基甲氧基化反应的方法
  申请人：五邑大学

  公开号：CN113666826A

  公开（公告）日：2021-11-19

  本发明公开了一种芳基或杂芳基甲氧基化反应的方法。所述方法，包括如下步骤：将底物、偶联剂、配体、溶剂、催化剂和碱混合均匀在惰性气体中反应，得到所述芳基或杂芳基甲氧基化合物。本发明采用价格低廉的卤化亚铜为催化剂，实现了在卤化亚铜催化下，配体调控芳基卤化物或杂芳基卤化物的甲氧基化反应，与现有技术的甲氧基化反应的方法比较，本发明所述方法的反应体系条件温和，催化剂和配体的使用量分别低至底物物质的量的5％，提高了催化效率；且所述方法对不同底物拓展发现对不同官能团的芳基卤化物或杂芳基卤化物有较好的兼容性。采用本发明所述方法制备的芳基或杂芳基甲氧基化合物的产率为36％‑89％。
• [EN] HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] AGENTS RECEPTEURS DE L'HISTAMINE H3, PREPARATION ET UTILISATIONS THERAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2005097740A1

  公开（公告）日：2005-10-20

  The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

  本发明公开了具有组合物(I)或其药学上可接受的盐的新颖化合物，其具有组胺H3受体拮抗剂或逆激动剂活性，以及制备这种化合物的方法。在另一实施例中，本发明公开了包含组合物(I)的药物组合物，以及使用它们治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
  申请人：Beavers Lisa Selsam

  公开号：US20100048580A1

  公开（公告）日：2010-02-25

  The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

  本发明公开了化合物(I)的新颖化合物或其药学上可接受的盐，其具有组胺H3受体拮抗剂或逆激动剂活性，以及制备这种化合物的方法。在另一实施方案中，本发明公开了包含化合物(I)的药物组合物，以及使用它们治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。